NCT04506242 2020-09-09Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung CancerCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2 Unknown74 enrolled